Acrually I had not, for whatever reason, though from reading the posts of others on the board I had a basic familiarity with Jay's history with the FDA and CytoDyn. Very compelling stuff here. Jay basically takes you to school on why CD10 was a joke and exactly how CD12 ended up being hobbled by the FDA. What surprises me is that such a convincing and clear case for the further study of leronlimab apparently fell on deaf ears at the NIH.

I feel like having seen this I have a much clearer understanding of why Dr Jay is with us. I dealt with a fair number of docs in my role in hospital QA, and this man impresses me tremendously as both an able researcher and a really good doctor. To say that we are in good hands would be an understatement. Thank you for posting, skezan.